



REVIEW

Open Access



Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin

Seong Yeol Choi^{1†}, Sungbin Lim^{1†}, Kyoung-hye Yoon^{2*}, Jin I. Lee^{3*} and Robert J. Mitchell^{1*} 

Abstract

In this review, we discuss violacein and prodigiosin, two chromogenic bacterial secondary metabolites that have diverse biological activities. Although both compounds were “discovered” more than seven decades ago, interest into their biological applications has grown in the last two decades, particularly driven by their antimicrobial and anticancer properties. These topics will be discussed in the first half of this review. The latter half delves into the current efforts of groups to produce these two compounds. This includes in both their native bacterial hosts and heterogeneously in other bacterial hosts, including discussing some of the caveats related to the yields reported in the literature, and some of the synthetic biology techniques employed in this pursuit.

Keywords: Prodigiosin, Violacein, Antibacterial, Anticancer, Secondary Metabolite, Production, Synthetic Biology

Introduction

Bacterial strains are capable of producing many different secondary metabolites, including anti-cancer and antibiotic drugs. Here, we discuss two such compounds that are gaining interest due to their diverse biological activities, namely violacein and prodigiosin. Both of these compounds are synthesized by Gram-negative hosts and have been shown in studies from a wide berth of groups to possess important biological activities, including as potent antibiotics against multidrug resistant pathogens. Although both compounds were “discovered” nearly a century ago in the mid-20th century [1–3], their biological activities are still being studied to this day. However, one critical factor limiting research with either

compound is their cost, which range from \$360 to \$760 per milligram [4]. Within this review, therefore, discussion will be given primarily to the biological activities of these compounds, focusing on ecological and medical considerations of both violacein and prodigiosin, as well as current methods to over-produce these remarkable compounds.

Violacein and Prodigiosin – Hydrophobic Bacterial Chromogenic Pigments

Prodigiosin and violacein are both colorful secondary metabolites, a trait that makes isolating and identifying the bacterial strains that produce these compounds in sufficient quantities easier. As shown in Fig. 1, violacein is a purple-hued bacterial pigment. The fact that this compound is produced by a range of natural bacterial strains [5–8], including *Chromobacterium* [9] and *Janthinobacterium* [10], and in a wide-array of environmental locales, including the deep seas [11], rivers [9, 12], agricultural and forest soils [8, 13, 14], within polar and alpine glacial regions [7, 15, 16], and even on the leaves of white

* Correspondence: kyounghyeyoon@yonsei.ac.kr; jinillee@yonsei.ac.kr; esgott@unist.ac.kr

[†]Seong Yeol Choi and Sungbin Lim contributed equally to this work.


²Department of Physiology, Mitohormesis Research Center, Yonsei University Wonju College of Medicine, Wonju, Gangwon-do, South Korea

³Division of Biological Science and Technology, College of Science and Technology, Yonsei University, Mirae Campus, Wonju, Gangwon-do, South Korea

¹School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, South Korea



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



clover [17] and the skin of amphibians [18], all suggest the production of violacein should be relatively advantageous for the host. However, the octanol-water partitioning coefficient ($\text{Log } P_{\text{OW}}$) for violacein is 3.34 [19, 20], classifying this compound as highly hydrophobic and suggesting it is not readily secreted by the host into the surrounding environment.

Similarly, prodigiosin is vibrant red in color (Fig. 1) and is produced by a number of different Gram-negative and Gram-positive bacterial strains, including *Serratia marcescens* [21] and *Streptomyces*. As a compound, prodigiosin is a member of the prodiginines, a group of chemicals with the same parent nucleus but differing side groups. For this review, emphasis will be given primarily to prodigiosin as this is the most extensively studied compound within this group. When compared with violacein, prodigiosin is even more hydrophobic, with a $\text{Log } P_{\text{OW}}$ of 5.16 [22].

Violacein and Prodigiosin as Antimicrobials

The antimicrobial activities of these two compounds have been extensively studied (Tables 1 and 2), particularly for violacein. It is historically recognized that very few Gram-negative bacteria are susceptible to violacein, data that is supported by independent groups in many recent studies [3, 39–41, 58]. The fact that violacein has been produced in recombinant strains of *E. coli*, as well as in *Salmonella typhimurium* VNP20009, *Enterobacter*

aerogenes IAM1183 and *Citrobacter freundii* ACCC 05411, with no clear detriment to the growth or viability of these strains [59–62] supports this further. However, individual studies from some groups recently claim violacein exhibits low MIC or growth inhibitory activities with Gram-negative strains [63–65]. Given the historicity and wide range of reports suggesting otherwise, the veracity of these studies needs to be demonstrated independently by other research groups.

In contrast, the activity of violacein against many different Gram-positive bacterial strains (Table 1), including *Staphylococcus*, *Bacillus* and *Streptococcus* [3, 40], is well established. Despite this, its spectrum does not extend to all Gram-positive strains. For instance, *Enterococcus faecalis* ATCC 29212 was not affected by the addition of violacein [66], while *Corynebacterium glutamicum* ATCC 21850 was genetically engineered to produce violacein [67]. It also exhibits antibiotic activities against *Mycobacterium tuberculosis* and *M. smegmatis*, which are acid-fast microbes, and the Gram-variable *Micrococcus luteus* [7, 68].

Stemming from its recognized activities against Gram-positive strains, many recent studies have evaluated the use of violacein against antibiotic-resistant strains of *S. aureus* [8, 41, 58, 66]. For instance, the minimal inhibitory concentrations (MICs) for several *S. aureus* associated with Bovine Mastitis were between 6.25 and 25.00 μM violacein, even though these strains displayed

Table 1 Prodigiosin's antibiotic activity against microorganisms

Microbe	Description	Reference
Bacteria		
Bacillus cereus		[23]
Bacillus subtilis		[24]
Enterobacter cloacae		[25]
Escherichia coli		[23, 25] [26]
Klebsiella aerogenes	Human pathogen	[25]
Pseudomonas aeruginosa	Human pathogen	[25]
Staphylococcus aureus	Human pathogen	[23, 25–27]
Streptococcus pyogenes	Human pathogen	[27]
Fungi		
Batrachochytrium dendrobatidis	Amphibian pathogen	[28]
Batrachochytrium salamandrivorans	Amphibian pathogen	[28]
Botrytis cinerea	Plant pathogen	[29]
Fusarium oxysporum	Plant pathogen	[30]
Mucor irregularis	Human pathogen	[31]
Mycosphaerella fijiensis	Plant pathogen	[32]
Phytophthora infestans	Plant pathogen	[30]
Pythium myriotylum	Plant pathogen	[30]
Rhizoctonia solani	Plant pathogen	[30, 33]
Sclerotium rolfsii	Plant pathogen	[30]
Virus		
HSV-1	Herpes	[34]
Protozoa		
Plasmodium falciparum	Malaria	[35, 36]
Trypanosoma cruzi	Parasitic euglenoids	[37]
Insect		
Aedes aegypti	Yellow fever mosquito	[38]
Anopheles stephensi	Malaria vector	[38]

penicillin, ampicillin and/or intermediary erythromycin resistance [58]. Moreover, violacein acted synergistically with penicillin [58], an idea that was expanded in another study [64]. A separate study using methicillin-resistant *S. aureus* (MRSA) reported MICs in basically the same range, *i.e.*, 7.5 to 30 μM [66], while research from our group found a multidrug-resistant *S. aureus* clinical isolate with resistance to seven different antibiotics was also susceptible to violacein [8]. In that study, the MICs for both the clinical isolate and the non-resistant type strain (*S. aureus* ATCC 25923) were identical (15 μM) while bactericidal effects against both were seen when 30 μM or more violacein was employed [8]. This proved the antibacterial mechanism used by violacein differs from that of the other antibiotics and also that cross-resistance was not present.

For both compounds, their antimicrobial activities stem in part due to their lipophilic natures. When introduced

into a bacterial culture, prodigiosin and violacein rapidly insert into the membranes of the microbe and disrupt their integrity, leading to ATP and protein leakage [22, 69, 70]. Interactions between violacein and bacterial membranes were recently modeled [70], and suggested that this compound does not embed very deeply within the lipid bilayer. The same study looked at the release of carboxyfluorescein from large unilamellar vesicles (LUVs) prepared using the lipids from three different bacteria, *i.e.*, *E. coli* ATCC 25922, *B. subtilis* PY79 and *S. aureus* ATCC 25923. They found, regardless of the strain, the LUVs were equally susceptible [70], implying *E. coli* cellular membranes are just as likely to be attacked by violacein and that its inherent resistance to violacein stems from the protective nature of the outer membrane, which absorbs this antibiotic and prevents its access to the cytoplasmic membrane. Recent work from our group studied this further, but from a different perspective, by asking

Table 2 Violacein's antibiotic activity against microorganisms

Microbe	Description	Reference
Bacteria		
Bacillus anthracis	Anthrax	[3]
Bacillus cereus		[39]
Bacillus licheniformis		[40]
Bacillus megaterium	Plant pathogen	[3, 40]
Bacillus mesentericus	Potential probiotics	[3]
Bacillus subtilis	Common soil bacteria	[3, 40]
Corynebacterium diphtheriae	Diphtheria	[3]
Neisseria meningitidis	Meningococcal disease	[3]
Pseudomonas aeruginosa	Human pathogen	[40, 41]
Staphylococcus aureus	Human pathogen	[3, 39–41]
Staphylococcus epidermidis		[3, 39]
Staphylococcus haemolyticus	Human pathogen	[3]
Streptococcus pneumoniae	Pneumonia	[3]
Viridans streptococci		[3]
Fungi		
Aspergillus flavus		[42]
Batrachochytrium dendrobatidis	Amphibian chytrid fungus	[18, 28, 43, 44]
Batrachochytrium salamandrivorans	Amphibian chytrid fungus	[28, 44]
Bipolaris leersia		[45]
Botrytis cinerea	Plant pathogen	[45–47]
Candida albicans	Yeast	[42]
Candida tropicalis	Yeast	[42]
Colletotrichum acutatum	Plant pathogen	[47]
Colletotrichum dematium	Plant pathogen	[45]
Colletotrichum glycines	Plant pathogen	[46]
Colletotrichum orbiculare	Plant pathogen, Affected by deoxyviolacein	[46]
Cryptococcus gastricus		[42]
Diaporthe nomurai		[45]
Fusarium lateritium	Plant pathogen	[45]
Fusarium oxysporum	Plant pathogen	[42, 46]
Fusarium solani	Plant pathogen	[45]
Gibberella zeae	Plant pathogen, Affected by deoxyviolacein	[46]
Magnaporthe grisea	Plant pathogen, Affected by deoxyviolacein	[46]
Penicillium expansum	Plant pathogen	[42]
Phytophthora capsici	Plant pathogen	[46]

Table 2 Violacein's antibiotic activity against microorganisms (Continued)

Microbe	Description	Reference
Bacteria		
Rhizoctonia solani	Plant pathogen, Affected by deoxyviolacein	[42, 46]
Rosellinia necatrix	Plant pathogen	[45]
Saccharomyces cerevisiae	Yeast	[3]
Sclerotinia sclerotiorum	Plant pathogen	[46]
Trichophyton rubrum	Athlete's foot fungus	[42]
Ustilaginoidea oryzae		[46]
Verticillium dahliae	Plant pathogen	[46]
Virus		
HSV-1	Herpes	[48]
Poliovirus type 2	Poliomyelitis	[48]
Simian rotavirus SA11	Rotavirus	[48]
Nematode		
Bursaphelenchus xylophilus	Pine wilt nematode	[49]
Caenorhabditis elegans		[50, 51]
Protozoa		
Acanthamoeba castellanii	Amoeba	[6]
Leishmania amazonensis	Leishmaniasis parasite	[52]
Plasmodium chabaudi	Malaria	[53]
Plasmodium falciparum	Malaria	[53, 54]
Rhynchomonas nasuta		[6]
Tetrahymena sp.		[6]
Trypanosoma brucei gambiense	Human parasite	[55]
Trypanosoma cruzi	Human parasite	[54]
Insect		
Drosophila melanogaster	Fruit flies	[56]
Spodoptera litura	Plant pest insects	[57]

how violacein acts as an antibiotic in nature if it is hydrophobic and remains embedded primarily within the membrane of the strain that produced it. It was found *C. violaceum* secretes violacein within membrane vesicles (MVs) [20]. These vesicles bud off of the bacterium as it grows and contained more violacein than proteins (mg/mg), increasing the apparent water solubility of violacein. Using *S. aureus* and a violacein-deficient *vioA* mutant, the violacein-carrying MVs were proven to be bactericidal, although a greater overall amount of violacein was required to achieve the same killing efficiencies as crude purified violacein. In contrast, MVs from the *vioA* mutant had no impact on *S. aureus* viabilities, proving violacein was the bactericidal factor responsible.

A recent study also performed molecular dynamic simulations with prodigiosin [71]. The authors found, in contrast to violacein, prodigiosin embedded itself much deeper within the membrane lipid bilayer, a finding that helps explain why this compound is effective against some Gram-negative strains as this would increase the chances for prodigiosin to penetrate the outer membrane and enter the cytoplasmic membrane. However, it still remains to be seen if MVs are also used by prodigiosin-producing strains to transport this antibiotic to susceptible microbes.

In addition to membrane disruption, prodigiosin apparently causes additional damage within the bacterium, including the generation of reactive oxygen species (ROS) [23, 72] and, based on the study by Darshan and Manonmani (2016) [23], interacting with the bacterial genomic DNA. This latter facet of its activities corroborates an earlier study where prodigiosin was shown to cleave double-stranded DNA *in vitro* [73], an activity that is mediated by oxidative radicals (*i.e.*, ROS) and requires the presence of a redox-active transition metal since the addition of either catalase or EDTA inhibited cleavage. Taken together, both studies suggest the ROS production by prodigiosin and its interactions with redox-active transition metals may act in concert *in vivo* to cause DNA damage within the bacterial cell, although this would benefit from further verification.

Prodigiosin and Violacein as Antifungals

In addition to their application towards bacterial pathogens, violacein (and its deoxyviolacein derivative) and prodigiosin also work widely and effectively against many pathogenic fungi (Tables 1 and 2). For violacein, representative examples of fungi that are susceptible include the plant pathogen *Rhizoctonia solani* [42, 46] and *Batrachochytrium dendrobatidis* [43, 44], a fungus that is lethal to amphibians. In the latter case, the presence of a violacein-producing bacterium, *J. lividum*, on the skin of the black-backed salamander (*Plethodon cinereus*) [44] or frog (*Rana muscosa*) [43] provided protection against *B. dendrobatidis*. Under these conditions, this bacterium was clearly able to produce a significant amount of violacein as the skin-associated concentrations with the frogs averaged around 100 μM , which was much higher than the 18 μM MIC needed to prevent mortality and morbidity caused by *B. dendrobatidis* based on the salamander study.

Although not studied as extensively, several reports have also discussed prodigiosin and its activities against different fungal species [30, 74–77]. Much like the two studies mentioned above, one group even looked at the ability of *S. marcescens* to protect *Acris blanchardi* (Blanchard's Cricket frog) from *B. dendrobatidis* infections, reporting a slight, yet significant, increase in

survival rates when compared against a *pig* mutant that is unable to synthesize this compound [77]. Moreover, although the mechanism of action is not fully understood, detailed observation of *S. marcescens* invading into fungus was reported recently [31]. In that study, prodigiosin increased the membrane permeability of target cell, enabling *S. marcescens* to invade into *F. oxysporum*. Given prodigiosin's ability to damage the target cell's membrane was also suggested as a mechanism of action against other bacterial cells [22], it would appear this compound has similar properties against organisms spanning different kingdoms.

Violacein and Prodigiosin as Nematicidal and Anti-Protozoan Agents

A benefit of violacein and prodigiosin for the producing bacteria is that it confers a survival advantage against competitors and predators, providing selective advantages against neighboring bacteria and an effective defense and deterrent against bacterivores, such as protozoa and nematodes (Tables 1 and 2).

Nematodes have caused detrimental disease to both humans and agriculture worldwide. Pine wilt disease, a serious epidemic that has devastated pine forests globally, especially in East Asia, is caused by the nematode *Bursaphelenchus xylophilus*. This nematode, also called pine wilt nematode, attacks the water transport system of pine trees, causing them to wilt and die [78]. Expensive nematicides have commonly been used to combat pine wilt nematode with little success. Recently, a violacein5'-O-glucoside derivative was constructed by expressing the glycosyltransferase (*YjiC*) from a *Bacillus* sp. in *E. coli* along with the *vioABCDE* [49]. This novel violacein derivative had increased water solubility and was an effective treatment against the pine wood nematode [49], suggesting its potential use in the future as an anti-nematodal agent against pine wilt disease.

Violacein also negatively impacted the nematode genetic model organism *C. elegans*. When fed on violacein-producing *Janthinobacterium*, *C. elegans* displayed developmental arrest in early larval stages [50]. Similar developmental arrest and delay was seen when violacein was expressed in *E. coli* OP50 [79] (Fig. 2), the normal laboratory diet of *C. elegans* [50]. Consumption of this compound induced the expression of several detoxification genes regulated by the insulin-like signaling pathway [80]. Interestingly, supplementation of unsaturated fatty acids, especially oleate, alleviated the worm growth and survival in violacein, whereas saturated fatty acids had no effect [79]. In addition to highlighting the anti-nematodal potential of violacein, studies in *C. elegans* may help also elucidate if a conserved mechanism of violacein-induced toxicity in metazoans exists. With the extensive genetic and molecular tools available for *C.*




Fig. 2 Violacein stunts the growth and development of *C. elegans*. (A) Lawn of *E. coli* strain OP50 (left) and violacein-expressing OP50 (OP50-vio, right). (B) Body length of worms grown on OP50 and OP50-vio from L1 larvae stage for 4 days. (C) Development of worms grown on OP50 and OP50-vio. Day 1 image show L1 synchronized worms that has never been fed. Scale bar = 100 µm. Figure originally published in [79]

elegans, exploring how unsaturated fatty acids are able to mitigate violacein's toxicity may provide a window into this mechanism, and may also shed light on its activities within cancer cells.

Anticancer Activities of Prodigiosin and Violacein

Another well-known characteristic of these two compounds is their anti-tumor activities. Cancer is the second leading cause of death globally [81], and although recent therapeutics have been developed for some cancers, still it remains as devastating as ever. In the laboratory, prodigiosin has been reported to kill human cancer cell lines by a process called programmed cell death or apoptosis. Prodigiosin can induce apoptosis in haematopoietic cancer cells [82], human lung cancer cells [83], B cells and T cells in chronic lymphocytic leukemia [84], gastric cancer cells [85], multidrug resistant breast cancer cells [86], colorectal cancer cells [87] and glioblastoma multiforme cancer cells [88] (Table 3).

Despite the strong evidence that prodigiosin can work against multiple types of cancer cells, how this compound targets cancer cell death by apoptosis is not yet clear. Prodigiosin can interact with and cleave DNA [73, 92], supporting one possible mechanism of cell death. Prodigiosin also facilitates proton and chloride ion symport and can affect the acidification of cellular compartments [94, 95], providing support for an alternative mechanism of cancer cell apoptosis [90]. Finally, prodigiosins also inhibit protein phosphatase activity *in vitro* [96, 97], suggesting another

possible mechanism of how this compound may inhibit cancer cell growth.

More recent studies have suggested that prodigiosin causes cell death by affecting a cellular process called autophagy. The process of autophagy causes an accumulation of specific vesicles in the cell called autophagosomes that can break down damaged organelles or proteins [98]. Autophagy has also been a target

Table 3 List of cell lines evaluated with prodigiosin

Cell Line	Description	References
95-D	Human highly metastatic lung cancer	[89]
B-CLL	Chronic lymphocytic leukemia	[84]
DLD1	Colorectal cancer	[87]
GLC4	Small cell lung cancer	[83]
A549	Lung cancer	[90]
HCT116	Colorectal cancer	[87, 91]
SW480	Colorectal cancer	[87, 91]
SW620	Colorectal cancer	[87]
HGT-1	Gastric cancer	[85]
HL-60	Haematopoietic cancer	[73, 82]
Jurkat	Haematopoietic cancer	[82, 92]
U87MG	Glioblastoma cancer	[88]
GBM8401	Glioblastoma cancer	[88]
MCF-7	Breast cancer	[86, 92]
MDA-MB-231	Breast cancer	[86, 93]
NSO	Haematopoietic cancer	[82]
Ramos	Haematopoietic cancer	[82]

for cancer therapy [99], especially due to the fact that this cellular process also regulates apoptosis in cancers [100]. In a recent laboratory study, prodigiosin treatment induced the death of glioblastoma cancer cells and reduced neurosphere growth, a marker associated with increased death in glioblastoma patients [88]. The authors further showed that apoptotic death of the glioblastoma cells by prodigiosin treatment was due to increased autophagy in the cancer cells. In another recent study, colorectal cancer cells that were treated with the chemical 5-fluorouracil, a common chemotherapy treatment for colorectal cancer, showed increased apoptosis in the presence of prodigiosin [91]. Interestingly, prodigiosin impaired autophagic flux which actually promoted cell death in the cancer cells in response to 5-fluorouracil.

Combination therapy, which uses two or more therapeutic agents as a cancer treatment, has become a main strategy in cancer therapy in recent years [101]. The use of prodigiosin in combination with other cancer therapies is a promising strategy that is currently being explored. As mentioned previously, 5-fluorouracil in combination with prodigiosin effectively killed colorectal cancer cells by increasing apoptosis [91]. In addition, a recent study showed that the combination of prodigiosin and PU-H71, a candidate therapy for triple negative breast cancer, induced apoptosis in a metastatic breast cancer cell line killing many of the cancer cells [93]. These studies, as well as others, confirm that prodigiosin promotes the killing of cancer cells in the laboratory and demonstrate that it is an excellent candidate for cancer therapy either as a combination therapy or singular treatment. However, whether this activity can actually translate to a treatment for cancer patients remains unknown. Several phase I and phase II clinical studies with various cancer patients have occurred with a prodigiosin derivative called obatoclox [102–105], and the jury is still out on whether prodigiosin is an effective therapy for human cancer patients.

Similar with prodigiosin, violacein is also a promising anti-tumor bacterial metabolite (Table 4). As with prodigiosin, violacein leads to mitochondrial dysfunction, brought on by mitochondrial membrane hyperpolarization, in MRC-5 and HeLa cells [111]. It was also confirmed in RAS-mutated metastatic melanoma cell lines that the autophagy process employed to resolve mitochondrial damage is impaired due to inhibition of AKT and AXL [115]. Subsequent processes followed a general apoptotic pathway leading to p38 MAP kinase phosphorylation, NF κ B pathway activation, and activation of caspases when treated with 1 μ M of violacein in HL60 [113]. However, in TF1, which is known to have apoptosis resistance, the IC₅₀ was still only 2 μ M despite co-treatment with inhibitors of pro-apoptotic caspases, leading the authors to conclude that violacein induces

Table 4 List of cell lines evaluated with violacein

Cell Line	Description	Ref
92.1	Uveal melanoma	[106]
A549	Lung cancer	[60, 107]
A431	Skin cancer	[60]
Caco-2	Heterogeneous epithelial colorectal adenocarcinoma	[108, 109]
CAL-27	Head and neck carcinoma cells	[110]
CHO-K1	Chinese Hamster Ovary cells	[111]
DLD1	Colorectal adenocarcinoma	[109]
EAT	Mouse Ehrlich ascites tumor	[112]
FaDu	Head and neck carcinoma cells	[110]
FRhK-4	Fetal kidney	[48]
HCT116	Colorectal adenocarcinoma	[60, 109]
HeLa	Hela cell, Cervix cancer	[60, 111]
Hep2	Hela-derived	[48]
HL60	Promyelocytic leukemia	[113]
HN5	Head and neck squamous cell carcinoma cells	[60]
HT29	Colorectal adenocarcinoma	[60, 108]
K562	Lymphoma	[113]
KM12	Colon cancer	[114]
MA104	Monkey Kidney epithelial cells	[48]
MCF7	Breast cancer	[60, 107]
MOLT-4	Acute lymphoblastic leukemia	[114]
MRC-5	Fetal lung fibroblast	[111]
NCI-H460	Non-small-cell lung cancer	[114]
OCM-1	Choroidal melanoma	[106]
PC3	Prostate cancer	[60]
SALTO	Head and neck carcinoma cells	[110]
SCC-15	Head and neck carcinoma cells	[110]
SKMEL-103	RAS-mutated metastatic melanoma	[115]
SKMEL-28	RAS-mutated metastatic melanoma	[115]
SW480	Colorectal adenocarcinoma	[109]
TF1	Erythroleukemia	[116]
U87	Glioblastoma	[107]
U937	Chronic myelogenous leukemia	[113]
V79	Chinese Hamster Fibroblast-like cell line from lung tissue	[114]
Vero	Monkey Kidney	[48]

cell death via the activation of a non-canonical mechanism of cell death [116]. Interestingly, an *in vitro* study showed that violacein inhibits PKA and PKC activity [117]. While the results do not exclude other possible targets, and whether this leads to cancer cell death *in vivo* awaits to be examined, it suggests PKA and PKC could be a direct target of violacein.

This sequence of cell death mechanisms resulting from mitochondrial damage brought on by violacein is due to the profound threat to the energy metabolism of cells. As a good indication of this, violacein has enhanced anti-cancer activities against some cell lines in hypoxia, such as HCT 116 (4.8-fold), HN5 (6.5-fold), HT29 (12.6-fold), and MCF7 (4-fold) [60]. Moreover, violacein treatment (1 μ M) led to the downregulated expression of chemokine/receptor CXCL12/CXCR4, which is important for angiogenesis [118]. Since carcinoma development without angiogenesis leads to hypoxic conditions, these results suggest violacein may actually induce the conditions within the tumor that increase its effectiveness as an anticancer agent, as was reported in one study [119].

Other studies have confirmed that oral administration of violacein contributes to NSAID-induced gastric damage healing. This led to a decrease in inflammatory cytokines, particularly TNF- α , and an increase in epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) [120]. These appear to play an essential role in healing angiogenesis and mucin secretion. In other words, violacein administered orally plays a role in inhibiting inflammation, maintaining the balance of cytokines, while also inhibiting apoptosis, angiogenesis, and promoting healing.

Immunomodulatory Activities of Prodigiosin and Violacein

Prodigiosin is also known to have immunosuppressive effects. Specifically, this compound shows suppressive effects on T-cell proliferation, while having no effect in B-cells [121]. Its mechanism of action is to inhibit expression of the interleukin-2 receptor α (IL-2R α) chain, an important contributor of T-cell activation [122]. In another study, the authors developed a prodigiosin-analogue molecule, PNU156804, which suppressed both T-cell and B-cell activation [123]. This compound also worked through inhibiting IL-2 dependent signaling, *i.e.*, not by preventing IL-2R α induction but rather by preventing activation of AP-1 and NF- κ B. Prodigiosin was also synergistically active when administered with cyclosporine A, each working through different pathways to suppress T-cell activation [124], while another study found it inhibited macrophage and NK killer cell activities and splenocyte proliferation [125].

Violacein was also shown to have immunomodulatory functions and inhibit inflammation. For instance, this compound had antipyretic, analgesic, and immunomodulatory reactions when orally administered to rats [126]. In ulcer rat models, violacein relieved inflammation of the gastrointestinal tract, possibly working through the COX-1 mediated pathways [120], while another study reported that, when injected directly into the

intraperitoneal cavity, violacein can have immunomodulatory effects by regulating cytokine production: it down-regulated the expression of IL-6 and TNF- α but induced expression of IL-10 [127].

Some of the immunomodulatory mechanisms and findings associated with violacein seem contradictory with the cancer studies, however. Unlike the above study that reported violacein inhibits TNF- α expression [127], TNF- α expression was elevated in HL60, and TNF receptor 1 signaling was also activated when this cell line was exposed to violacein [113]. It is also known to increase the expression of TNF- α and upregulate the p53-dependent mitochondrial pathway in MCF-7 [128], while treatment with violacein also induced TNF- α expression in Raw 264.7 and ANA-1 cells [129]. These differences may be due to the experimental protocols, though, as the above studies were performed *in vitro*, *i.e.*, violacein treatment directly into human or murine cell cultures [128, 129], rather than *in vivo*, *i.e.*, the oral administration or injection of violacein into the digestive tract or intraperitoneal cavity [120, 126, 127]. In other words, vastly different results may result depending on the method of administration and the type of cells, but all of the above studies confirmed that violacein has immunomodulatory aspects.

Bioproduction - Measurement of Prodigiosin and Violacein – Spectrophotometry vs. HPLC

The classical method for prodigiosin extraction from the bacterial host and culture is to use acidified ethanol (4% 1M HCl v/v) to prevent the rapid decomposition of this molecule when above pH 5. The impurities present in the extracted prodigiosin are then removed using a solvent such as dichloromethane or n-hexane:chloroform and the final product purified through chromatography [130–132].

The simplest way to measure the extracted prodigiosin is to use a spectrophotometer using an absorption wavelength of 530–540 nm and convert this to the concentration using an extinction coefficient (ϵ) and the Beer–Lambert law. However, this is not without issue as the value of ϵ varies from study to study. Traditionally, the value of ϵ_{535} is 0.159 L/mg-cm [133]. The most detailed study on the extinction coefficient of prodigiosin is Domröse et al. (2015) [130], where ϵ_{535} was calculated to be 0.4322 L/mg-cm in acidified ethanol, a value that was confirmed through quantitative ¹H-NMR. This value is near identical with that reported by another group, *i.e.*, $\epsilon_{535} = 0.4311$ L/mg-cm [134]. Consequently, due to the difference in the extinction coefficients, the prodigiosin concentration using the classical ϵ value will be over-estimated by 270%.

Similarly, violacein has often been quantified using a spectrophotometer and its absorbance peaks at 575-

590nm [8, 135–137]. However, because of differences in reported ϵ between research groups, the yields claimed in the literature are inconsistent. For example, the ϵ values for violacein include, from lowest to highest, $\epsilon_{570} = 10.955$ L/g-cm in ethanol [138], $\epsilon = 29.700$ L/g-cm [137], $\epsilon_{565} = 31.3$ L/g-cm in acetone-water [139], $\epsilon_{570} = 46$ L/g-cm in ethanol [67], $\epsilon_{575} = 56.010$ L/g-cm in ethanol [135] and $\epsilon_{575} = 74.3$ L/g-cm in ethanol [140]. This disparity was raised in the study by Rodrigues et al. (2013) [140] and in previous reviews [141, 142], potentially inflating the violacein yields by as much as 670%.

To address this issue, Rodrigues et al. (2013) [140] elected to quantify violacein through HPLC [140], a protocol that has been successfully applied within several of our own studies [20, 143, 144]. At present, similar protocols have not been applied to quantify prodigiosin and HPLC may consolidate the yields in the literature, an idea that should be evaluated further. However, given the wide-spread problems raised by this issue, the concentrations of these two compounds reportedly produced in the literature will not be discussed, but rather the qualitative results of the studies.

Production by Natural Isolates

As discussed above, a wide-range of natural bacterial strains are capable of synthesizing violacein and prodigiosin. It should come as no surprise, therefore, that researchers have sought out a variety of strains for the lab scale production and application of these two compounds. For instance, *S. marcescens* FZSF02 was isolated from the soil in the region of Fuzhou, China, and is capable of producing prodigiosin in sufficient quantities that it reportedly pellets out of solution [145]. Another natural strain, *S. marcescens* MO-1 was isolated from a grasshopper [146] while *S. marcescens* UCP1459 and *S. marcescens* UTM1 were isolated from semi-arid soil in Brazil and an oxidation pond in Malaysia, respectively [147, 148]. A related bacterium, *S. rubidaea*, also produced prodigiosin and was initially isolated from a spoiled coconut, where it was discovered since it changed the color of the inside of the coconut, making it pink [149].

Similarly, violacein production has been studied in different natural strains. For instance, production of this compound in *C. violaceum* CCT 3496 was increased around 2.5-fold when tryptone and yeast extract were added, but the yields dropped with glucose [135]. In a separate study, optimization in *Duganella* sp. B2 found tryptophan, beef extract, and potassium nitrate were all major factors impacting violacein yields [138] while in *Massilia* sp. EP15224, an isolate known to be closely related to *Duganella* sp., the MM2 broth used to cultivate this strain was improved by adjusting the amount of

phosphate, leading to faster production rates and slightly better final violacein yields [150].

Some violacein-producing bacteria are also psychrotrophic, such as strain RT102, which is related with *J. lividum*, reported by Nakamura et al (2003) [40]. The authors found that the conditions leading to optimum production levels were a slightly acid pH of 6, the growth temperature set to 20°C and with 1 mg/L of dissolved oxygen. Although not as psychrophilic as RT102, *J. lividum* was also successfully used to produce violacein, albeit at 25 °C and a pH of 7.0 [65]. Notably, in this study, the addition of 0.2 mg/mL of the antibiotic of silver ampicillin improved the yields by a factor of 1.3 while glycerol was used as a carbon source, a choice the authors claimed improves the violacein production relative to the cell mass.

The idea of using ampicillin and glycerol to increase violacein yields was actually reported more than a decade earlier in the study by Pantanella et al (2007), where glycerol enhanced violacein production levels by approximately 12-fold, while ampicillin led to an estimated 3-fold increase [136]. These factors, unfortunately, were not additive when used together – the maximum level with glycerol with or without ampicillin were basically identical.

The use of more natural feed stocks was also considered, as in the case with *C. violaceum* UTM5 where agricultural wastes were used [151], or in a separate study where liquid pineapple waste was used as the carbon source along with addition of L-tryptophan [41]. However, as noted above, since these papers do not provide the extinction coefficient and did not use HPLC techniques when quantifying their yields, it is difficult to directly compare their results with other studies.

Random Mutations to Enhance Prodigiosin Production

One strategy used by researchers to enhance production of prodigiosin is to generate random mutations within the genome of the natural host, typically with radiation. Since prodigiosin is a red pigment, screening is a simple and quick method for researchers to identify those colonies that overproduce this compound based on their color intensity. This was successfully used by one group with microwave irradiation to increase the prodigiosin yields from *S. marcescens* jx1 by just over two-fold [26], while a separate group used gamma irradiation [152]. In the latter study, the authors varied more than just the radiation dose and rate, including the pH and inoculum size, to identify conditions that optimize for prodigiosin production. However, as in the microwave radiation study, the yields were only improved by about 2-fold.

Heterogeneous Expression and Metabolic Pathway Engineering to Increase Prodigiosin and Violacein Yields

The above yields, although definitely improved, are not very significant and highlight potential limitations linked with random mutation studies, namely that improvements may not be very substantial, particularly when they involve complex metabolic pathways encoded in multiple genes such as those involved in prodigiosin biosynthesis. As such, researchers have often sought to clone and express the genes in other hosts where the metabolic and biosynthetic pathways can be engineered.

The prodigiosin gene cluster (*pig*) includes many genes, *pigA* to *pigN*, but may vary in gene order as well as include some auxiliary genes depending on the bacterial host [153, 154]. During the mid-20th century, studies in prodigiosin biosynthesis focused on related molecular components and constructing the pathway [21, 155–157], including the role of quorum sensing mechanisms [158–161], while recent studies have provided a more detailed understanding of the biosynthetic pathways involved [153, 154]. Violacein research has followed a similar path, with the biosynthetic pathway first mapped in 1991 [162] and the roles of the individual genes and enzymes characterized further in the early 2000's [163, 164]. In addition, during the same period many articles, were published discussing the roles of quorum sensing in the production of this metabolite [165–167]. This led to the eventual development and application of *C. violaceum* CV026 as a quorum-sensing reporter strain, as it visually responded to the presence of acyl homoserine lactones (AHLs) with the production or inhibition of violacein synthesis [166, 168, 169]. Recently, this strain was reclassified as *C. subtsugae* [170].

As the last two decades have seen sequencing techniques and comparative genome analyses dramatically improve, a new era of prodigiosin and violacein production has opened. Gene clusters related with prodigiosin production were sequenced, analyzed and compared among different species and subspecies [171, 172], as have the genomes of numerous violacein-producing bacteria [173–175], particularly by Dr. Brooke Jude at Bard University who, in the last couple of years, has published several genomes [176–179]. Of particular note, one of the *Janthinobacter* sp. sequenced by her group actually lacked the genes for violacein but carried the *pig* gene cluster, allowing it to produce prodigiosin [180]. They concluded that, since this strain was isolated from the region where other violacein-producing strains were also located, including other *Janthinobacter* sp., the production of prodigiosin by this strain may represent a combined effort by the two groups to combat other bacterial species.

All of this information will aid researchers in further efforts to clone and express the genes required in other bacterial strains. This is not to say that this has not been done already, as a few groups reported the heterogeneous production of prodigiosin [130, 181], one as far back as 1984 [182]. However, only one study truly sought to use the new host, in this case *Pseudomonas putida* KT2440, as a platform for the production of this compound [130]. In their study, the authors introduced the *pig* cluster randomly into the genome of *P. putida* using a plasmid bearing a transposon and screened the resulting clones for prodigiosin production, looking for insertions where the cluster was expressed by a strong promoter. Using this method, they were able to increase prodigiosin production on agar plates by approximately five-fold over the original *S. marcescens* and as much as 94 mg/L, based on their quantification methods, in liquid cultures.

In contrast, the expression of violacein in other bacterial hosts is widespread, with the *vioABCDE* genes cloned and expressed within many plasmids and bacterial hosts. Some examples of this include *Citrobacter freundii* [61, 62], *Klebsiella aerogenes* (formerly *Enterobacter aerogenes*) [62] and *E. coli* [62, 140, 162, 183–185]. Other studies have sought to improve on the violacein yields through synthetic biology, often with *E. coli* as the host [54, 186], albeit not always for purification, as illustrated in two recent studies where its expression was used as a bioreporter [187, 188]. One prime example where synthetic biology was employed to improve violacein production is the study by Jeshek et al. (2016) where they introduced the Reduced Libraries algorithm [189]. These used this system to design smart combinatorial libraries for pathway optimization based on the ribosomal binding sites and, in this case, focused on increasing violacein production while minimizing that of deoxyviolacein. A second group used a different approach and elected to express each gene independently by their own promoter [59]. By controlling the strengths of each individual promoter, and using a combinatorial assembly of the genes, they were able to increase the violacein titers by more than 60-fold over the control, where each gene was expressed under the T₇ promoter. In addition to *E. coli*, other hosts have been used for the heterogeneous production of violacein, including yeasts [190, 191]. One such study used *Yarrowia lipolytica*, an oleaginous yeast, as the host, where the *vio* genes were expressed using three different promoters and assembled using the Golden Gate assembly method to build combinatorial pathway libraries [191]. From this, three yeast strains, each producing a different chromogenic compound, i.e., violacein, deoxyviolacein and proviolacein, were constructed.




Fig. 3 Number of research articles related with prodigiosin and violacein published each year according to the data available at the NCBI PubMed website [192]. (Accessed Jan 20th, 2021)

Conclusions

This review presented many biological traits of both prodigiosin and violacein reported in the recent and current literature. Fig. 3 is a plot showing the number of peer-reviewed articles listed in the National Center for Biotechnology Information's PubMed website [192] for each year, providing visual evidence of the growing interest into these two compounds and their activities. Although the numbers may not be as great as some other hot-topics, the data makes it clear that many research groups continue to study and explore the biological activities of these two compounds and different methods for producing them in greater quantities. As this field continues to expand and mature, other derivatives of violacein and prodigiosin are expected to move towards clinical trials as antimicrobials and for the treatment of human diseases, including cancer, as was noted above for obato-clax. This will be supported in no small part by synthetic biologists and chemical engineers who are currently developing novel and more efficient protocols and strains to increase the productivity and yields of these two secondary metabolites, a trend that is also expected to reduce the costs of these compounds, which at present are too high for conventional medical research.

Acknowledgements

Funding was provided through the National Research Foundation of Korea under the Mid-Career Project (Grant No. 2020R1A2C2012158), the General Research Project (Grant No. 2020R1F1A1073848), and the Early Career Research Project (Grant No. 2019R1C1C1008708). We appreciate the support.

Authors' contributions

SYC, SL, KHY, JIL and RJM wrote the article. The author(s) read and approved the final manuscript.

Funding

Funding was provided through the National Research Foundation of Korea under the Mid-Career Project (Grant No. 2020R1A2C2012158), the General Research Project (Grant No. 2020R1F1A1073848), and the Early Career Research Project (Grant No. 2019R1C1C1008708). We appreciate the support.

Availability of data and materials

None.

Declarations

Ethics approval and consent to participate

None.

Consent for publication

All authors agree with publishing this article within *The Journal of Biological Engineering*

Competing interests

The authors declare no competing interests with the publishing of this article

Received: 25 January 2021 Accepted: 3 March 2021

Published online: 11 March 2021

References

1. Wasserman HH, Mc KJ, Santer UV. Studies related to the biosynthesis of prodigiosin in *Serratia marcescens*. *Biochem Biophys Res Commun*. 1960;3: 146–9.
2. Rapoport H, Holden KG. The Synthesis of Prodigiosin. *J Am Chem Soc*. 1962; 84(4):635–42.
3. Lichstein HC, Vandesand VF. Violacein, an Antibiotic Pigment Produced by *Chromobacterium-Violaceum*. *J Infect Dis*. 1945;76(1):47–51.
4. Sigma-Aldrich U.S. website. <https://www.sigmaaldrich.com/>. Accessed 20 Jan 2021.
5. Yang LH, Xiong H, Lee OO, Qi SH, Qian PY. Effect of agitation on violacein production in *Pseudoalteromonas luteoviolacea* isolated from a marine sponge. *Lett Appl Microbiol*. 2007;44(6):625–30.
6. Matz C, Webb JS, Schupp PJ, Phang SY, Penesyan A, Egan S, Steinberg P, Kjelleberg S. Marine biofilm bacteria evade eukaryotic predation by targeted chemical defense. *PLoS One*. 2008;3(7):e2744.

7. Hakvag S, Fjaervik E, Klinkenberg G, Borgos SEF, Josefsen KD, Ellingsen TE, Zotchev SB. Violacein-Producing *Collimonas* sp from the Sea Surface Microlayer of Coastal Waters in Trondelag, Norway. *Mar Drugs*. 2009;7(4):576–88.
8. Choi SY, Kim S, Lyuck S, Kim SB, Mitchell RJ. High-level production of violacein by the newly isolated *Duganella violaceinigra* str. NI28 and its impact on *Staphylococcus aureus*. *Sci Rep*. 2015;5:15598.
9. Moss MO, Ryall C, Logan NA. Classification and Characterization of Chromobacteria from a Lowland River. *J Gen Microbiol*. 1978;105(Mar):11–21.
10. Osullivan J, Mccullough J, Johnson JH, Bonner DP, Clark JC, Dean L, Trejo WH. Janthinocin-a, Janthinocin-B and Janthinocin-C, Novel Peptide Lactone Antibiotics Produced by *Janthinobacterium-Lividum*. 1. Taxonomy, Fermentation, Isolation, Physicochemical and Biological Characterization. *J Antibiot*. 1990;43(8):913–9.
11. Yada S, Wang Y, Zou Y, Nagasaki K, Hosokawa K, Osaka I, Arakawa R, Enomoto K. Isolation and characterization of two groups of novel marine bacteria producing violacein. *Mar Biotechnol*. 2008;10(2):128–32.
12. Riveros R, Haun M, Duran N. Effect of Growth-Conditions on Production of Violacein by *Chromobacterium-Violaceum* (Bb-78 Strain). *Braz J Med Biol Res*. 1989;22(5):569–77.
13. Aranda S, Montes-Borrego M, Landa BB. Purple-Pigmented Violacein-Producing *Duganella* spp. Inhabit the Rhizosphere of Wild and Cultivated Olives in Southern Spain. *Microb Ecol*. 2011;62(2):446–59.
14. Li WJ, Zhang YQ, Park DJ, Li CT, Xu LH, Kim CJ, Jiang CL. *Duganella violaceinigra* sp nov., a novel mesophilic bacterium isolated from forest soil. *Int J Syst Evol Micr*. 2004;54:1811–4.
15. Baricz A, Teban A, Chiriac CM, Szekeres E, Farkas A, Nica M, Dascălu A, Opreșan C, Lavin P, Coman C. Investigating the potential use of an Antarctic variant of *Janthinobacterium lividum* for tackling antimicrobial resistance in a One Health approach. *Sci Rep*. 2018;8(1):15272.
16. Kim SJ, Shin SC, Hong SG, Lee YM, Lee H, Lee J, Choi IG, Park H. Genome Sequence of *Janthinobacterium* sp Strain PAMC 25724, Isolated from Alpine Glacier Cryoconite. *J Bacteriol*. 2012;194(8):2096.
17. Kampfer P, Wellner S, Lohse K, Martin K, Lodders N. *Duganella phyllosphaerae* sp. nov., isolated from the leaf surface of *Trifolium repens* and proposal to reclassify *Duganella violaceinigra* into a novel genus as *Pseudoduganella violaceinigra* gen. nov., comb. nov. (vol 35, pg 19, 2012). *Syst Appl Microbiol*. 2012;35(4):278.
18. Brucker RM, Harris RN, Schwantes CR, Gallaher TN, Flaherty DC, Lam BA, Minbiole KPC. Amphibian Chemical Defense: Antifungal Metabolites of the Microsymbiont *Janthinobacterium lividum* on the Salamander *Plethodon cinereus*. *J Chem Ecol*. 2008;34(11):1422–9.
19. Suryawanshi RK, Patil CD, Borase HP, Narkhede CP, Stevenson A, Hallsworth JE, Patil SV. Towards an understanding of bacterial metabolites prodigiosin and violacein and their potential for use in commercial sunscreens. *Int J Cosmetic Sci*. 2015;37(1):98–107.
20. Choi SY, Lim S, Cho G, Kwon J, Mun W, Im H, Mitchell RJ. *Chromobacterium violaceum* delivers violacein, a hydrophobic antibiotic, to other microbes in membrane vesicles. *Environ Microbiol*. 2020;22(2):705–13.
21. Williams RP. Biosynthesis of prodigiosin, a secondary metabolite of *Serratia marcescens*. *Appl Microbiol*. 1973;25(3):396–402.
22. Suryawanshi RK, Patil CD, Koli SH, Hallsworth JE, Patil SV. Antimicrobial activity of prodigiosin is attributable to plasma-membrane damage. *Nat Product Res*. 2016;31(5):572–7.
23. Darshan N, Manonmani HK. Prodigiosin inhibits motility and activates bacterial cell death revealing molecular biomarkers of programmed cell death. *AMB Express*. 2016;6(1):50.
24. Danevčič T, Borič Vezjak M, Tabor M, Zorec M, Stopar D. Prodigiosin Induces Autolysins in Actively Grown *Bacillus subtilis* Cells. *Front Microbiol*. 2016;7:27.
25. Li D, Liu J, Wang X, Kong D, Du W, Li H, Hse CY, Shupe T, Zhou D, Zhao K. Biological Potential and Mechanism of Prodigiosin from *Serratia marcescens* Subsp. *lawsoniana* in Human Choriocarcinoma and Prostate Cancer Cell Lines. *Int J Mol Sci*. 2018;19(11):3465.
26. Liu X, Wang Y, Sun S, Zhu C, Xu W, Park Y, Zhou H. MUTANT BREEDING OF *Serratia marcescens* STRAIN FOR ENHANCING PRODIGIOSIN PRODUCTION AND APPLICATION TO TEXTILES. *Prep Biochem Biotechnol*. 2013;43(3):271–84.
27. Lapenda JC, Silva PA, Vicalvi MC, Sena KXFR, Nascimento SC. Antimicrobial activity of prodigiosin isolated from *Serratia marcescens* UFPEDA 398. *World J Microbiol Biotechnol*. 2014;31(2):399–406.
28. Woodhams DC, LaBumbard BC, Barnhart KL, Becker MH, Bletz MC, Escobar LA, Flechas SV, Forman ME, Iannetta AA, Joyce MD, et al. Prodigiosin, Violacein, and Volatile Organic Compounds Produced by Widespread Cutaneous Bacteria of Amphibians Can Inhibit Two Batrachochytrium Fungal Pathogens. *Microb Ecol*. 2018;75(4):1049–62.
29. Someya N, Nakajima M, Hirayae K, Hibi T, Akutsu K. Synergistic Antifungal Activity of Chitinolytic Enzymes and Prodigiosin Produced by Biocontrol Bacterium, *Serratia marcescens* Strain B2 against Gray Mold Pathogen, *Botrytis cinerea*. *J General Plant Pathol*. 2001;67(4):312–7.
30. John Jimtha C, Jishma P, Sreelekha S, Chithra S, Radhakrishnan EK. Antifungal properties of prodigiosin producing rhizospheric *Serratia* sp. *Rhizosphere*. 2017;3:105–8.
31. Hazarika DJ, Gautom T, Parveen A, Goswami G, Barooah M, Modi MK, Boro RC. Mechanism of interaction of an endofungal bacterium *Serratia marcescens* D1 with its host and non-host fungi. *PLoS One*. 2020;15(4):e0224051.
32. Gutiérrez-Román MI, Holguín-Meléndez F, Dunn MF, Guillén-Navarro K, Huerta-Palacios G. Antifungal activity of *Serratia marcescens* CFFSUR-B2 purified chitinolytic enzymes and prodigiosin against *Mycosphaerella fijiensis*, causal agent of black Sigatoka in banana (*Musa* spp.). *BioControl*. 2015;60(4):565–72.
33. Someya N, Kataoka N, Komagata T, Hirayae K, Hibi T, Akutsu K. Biological Control of Cyclamen Soilborne Diseases by *Serratia marcescens* Strain B2. *Plant Disease*. 2000;84(3):334–40.
34. Suryawanshi RK, Koujah L, Patil CD, Ames JM, Agelidis A, Yadavalli T, Patil SV, Shukla D. Bacterial Pigment Prodigiosin Demonstrates a Unique Antiherpesvirus Activity That Is Mediated through Inhibition of Prosurvival Signal Transducers. *J Virol*. 2020;94(13):e00251-20.
35. Isaka M, Jaturapat A, Kramyu J, Tanticharoen M, Thebtaranonth Y. Potent In Vitro Antimalarial Activity of Metacycloprodigiosin Isolated from *Streptomycespectabilis* BCC 4785. *Antimicrobial Agents Chemother*. 2002;46(4):1112–3.
36. Papireddy K, Smilkstein M, Kelly JX, Shweta SSM, Alhamadsheh M, Haynes SW, Challis GL, Reynolds KA. Antimalarial Activity of Natural and Synthetic Prodiginines. *J Med Chem*. 2011;54(15):5296–306.
37. Genes C, Baquero E, Echeverri F, Maya JD, Triana O. Mitochondrial dysfunction in *Trypanosoma cruzi*: the role of *Serratia marcescens* prodigiosin in the alternative treatment of Chagas disease. *Parasit Vectors*. 2011;4:66.
38. Patil CD, Patil SV, Salunke BK, Salunke RB. Prodigiosin produced by *Serratia marcescens* NMCC46 as a mosquito larvicidal agent against *Aedes aegypti* and *Anopheles stephensi*. *Parasitol Res*. 2011;109(4):1179–87.
39. Im H, Choi SY, Son S, Mitchell RJ. Combined Application of Bacterial Predation and Violacein to Kill Polymicrobial Pathogenic Communities. *Sci Rep*. 2017;7(1):14415.
40. Nakamura Y, Asada C, Sawada T. Production of antibacterial violet pigment by psychrotropic bacterium RT102 strain. *Biotechnol Bioproc E*. 2003;8(1):37–40.
41. Aruldass CA, Rubiyatno VCK, Ahmad WA. Violet pigment production from liquid pineapple waste by *Chromobacterium violaceum* UTM5 and evaluation of its bioactivity. *Rsc Adv*. 2015;5(64):51524–36.
42. Sasidharan A, Sasidharan NK, Amma DBNS, Vasu RK, Nataraja AV, Bhaskaran K. Antifungal activity of violacein purified from a novel strain of *Chromobacterium* sp NIIST (MTCC 5522). *J Microbiol*. 2015;53(10):694–701.
43. Harris RN, Brucker RM, Walke JB, Becker MH, Schwantes CR, Flaherty DC, Lam BA, Woodhams DC, Briggs CJ, Vredenburg VT, et al. Skin microbes on frogs prevent morbidity and mortality caused by a lethal skin fungus. *ISME J*. 2009;3(7):818–24.
44. Becker MH, Brucker RM, Schwantes CR, Harris RN, Minbiole KPC. The Bacterially Produced Metabolite Violacein Is Associated with Survival of Amphibians Infected with a Lethal Fungus. *Appl Environ Microb*. 2009;75(21):6635–8.
45. Shirata A, Tsukamoto T, Yasui H, Hata T, Hayasaka S, Kojima A, Kato H. Isolation of bacteria producing bluish-purple pigment and use for dyeing. *Jarq-Jpn Agr Res Q*. 2000;34(2):131–40.
46. Wang H, Wang F, Zhu X, Yan Y, Yu X, Jiang P, Xing X-H. Biosynthesis and characterization of violacein, deoxyviolacein and oxyviolacein in heterologous host, and their antimicrobial activities. *Biochem Eng J*. 2012;67:148–55.
47. Lee Y-R, Mitchell RJ, Whang K-S. Isolation and characterization of antifungal violacein producing bacterium *Collimonas* sp. DEC-B5. *Korean J Microbiol*. 2016;52(2):212–9.

48. Andrighetti-Frohner CR, Antonio RV, Creczynski-Pasa TB, Barardi CRM, Simoes CMO. Cytotoxicity and potential antiviral evaluation of violacein produced by *Chromobacterium violaceum*. *Mem I Oswaldo Cruz*. 2003;98(6):843–8.
49. Lee YJ, Bashyal P, Pandey RP, Sohng JK. Enzymatic and Microbial Biosynthesis of Novel Violacein Glycosides with Enhanced Water Solubility and Improved Anti-nematode Activity. *Biotechnol Bioproc E*. 2019;24(2):366–74.
50. Hornung C, Poehlein A, Haack FS, Schmidt M, Dierking K, Pohlen A, Schulenburg H, Blokesch M, Plener L, Jung K, Bonge A, Krohn-Molt I, Utpatel C, Timmermann G, Spieck E, Pommerening-Röser A, Bode E, Bode HB, Daniel R, Schmeisser C, Streit WR. The *Janthinobacterium* sp. HH01 genome encodes a homologue of the *V. cholerae* CqsA and *L. pneumophila* LqsA autoinducer synthases. *PLoS One*. 2013;8(2):e55045.
51. Leon LL, Miranda CC, De Souza AO, Durán N. Antileishmanial activity of the violacein extracted from *Chromobacterium violaceum*. *J Antimicrob Chemother*. 2001;48(3):449–50.
52. Leon LL, Miranda CC, De Souza AO, Duran N. Antileishmanial activity of the violacein extracted from *Chromobacterium violaceum*. *J Antimicrob Chemother*. 2001;48(3):449–50.
53. Lopes SCP, Blanco YC, Justo GZ, Nogueira PA, Rodrigues FLS, Goelnitz U, Wunderlich G, Facchini G, Brocchi M, Duran N, et al. Violacein Extracted from *Chromobacterium violaceum* Inhibits *Plasmodium* Growth In Vitro and In Vivo. *Antimicrobial Agents Chemother*. 2009;53(5):2149–52.
54. Bilsland E, Tavella TA, Krogh R, Stokes JE, Roberts A, Ajioka J, Spring DR, Andricopulo AD, Costa FTM, Oliver SG. Antiplasmodial and trypanocidal activity of violacein and deoxyviolacein produced from synthetic operons. *BMC Biotechnol*. 2018;18(1):22.
55. Rahul S, Chandrashekar P, Hemant B, Bipinchandra S, Mouray E, Grellier P, Satish P. In vitro antiparasitic activity of microbial pigments and their combination with phytosynthesized metal nanoparticles. *Parasitol Int*. 2015;64(5):353–6.
56. Lozano GL, Guan C, Cao Y, Borlee BR, Broderick NA, Stabb EV, Handelsman J. A Chemical Counterpunch: *Chromobacterium violaceum* ATCC 31532 Produces Violacein in Response to Translation-Inhibiting Antibiotics. *mBio*. 2020;11(3):e00948–20.
57. Baskar K, Ignacimuthu S. Bioefficacy of violacein against Asian armyworm *Spodoptera litura* Fab. (Lepidoptera: Noctuidae). *J Saudi Soc Agric Sci*. 2012;11(1):73–7.
58. Cazoto LL, Martins D, Ribeiro MG, Duran N, Nakazato G. Antibacterial activity of violacein against *Staphylococcus aureus* isolated from Bovine Mastitis. *J Antibiot*. 2011;64(5):395–7.
59. Jones JA, Vernacchio VR, Lachance DM, Lebovich M, Fu L, Shirke AN, Schultz VL, Cress B, Linhardt RJ, Koffas MA. ePathOptimize: A Combinatorial Approach for Transcriptional Balancing of Metabolic Pathways. *Sci Rep*. 2015;5:11301.
60. Hashimi SM, Xu TF, Wei MQ. Violacein anticancer activity is enhanced under hypoxia. *Oncol Rep*. 2015;33(4):1731–6.
61. Yang C, Jiang PX, Xiao S, Zhang C, Lou K, Xing XH. Fed-batch fermentation of recombinant *Citrobacter freundii* with expression of a violacein-synthesizing gene cluster for efficient violacein production from glycerol. *Biochem Eng J*. 2011;57:55–62.
62. Jiang PX, Wang HS, Zhang C, Lou K, Xing XH. Reconstruction of the violacein biosynthetic pathway from *Duganella* sp B2 in different heterologous hosts. *Appl Microbiol Biot*. 2010;86(4):1077–88.
63. Asencio G, Paris Lavin, Karen Alegre A, et al. Antibacterial activity of the Antarctic bacterium *Janthinobacterium* sp. SMN 33.6 against multi-resistant Gram-negative bacteria *Electronic Journal of Biotechnology*. 2014;17:1–5.
64. Subramaniam S, Ravi V, Sivasubramanian A. Synergistic antimicrobial profiling of violacein with commercial antibiotics against pathogenic microorganisms. *Pharm Biol*. 2014;52(1):86–90.
65. Kaneli M, Mandic M, Kalakona M, Vasilakos S, Kekos D, Nikodinovic-Runic J, Topakas E. Microbial Production of Violacein and Process Optimization for Dyeing Polyamide Fabrics With Acquired Antimicrobial Properties. *Front Microbiol*. 2018;9:1495.
66. Martins D, Costa FTM, Brocchi M, Duran N. Evaluation of the antibacterial activity of poly-(D,L-lactide-co-glycolide) nanoparticles containing violacein. *J Nanopart Res*. 2011;13(1):355–63.
67. Sun H, Zhao D, Xiong B, Zhang C, Bi C. Engineering *Corynebacterium glutamicum* for violacein hyper production. *Microb Cell Fact*. 2016;15(1):148.
68. Mojib N, Philpott R, Huang JP, Niederweis M, Bej AK. Antimycobacterial activity in vitro of pigments isolated from Antarctic bacteria. *Anton Leeuw Int J G*. 2010;98(4):531–40.
69. Aruldass CA, Masalamany SRL, Venil CK, Ahmad WA. Antibacterial mode of action of violacein from *Chromobacterium violaceum* UTM5 against *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* (MRSA). *Environ Sci Pollut Res*. 2017;25(6):5164–80.
70. Cauz ACG, Carretero GPB, Saraiva GKV, Park P, Mortara L, Cuccovia IM, Brocchi M, Gueiros-Filho FJ. Violacein Targets the Cytoplasmic Membrane of Bacteria. *ACS Infect Dis*. 2019;5(4):539–49.
71. Ravindran A, Anishetty S, Pennathur G. Molecular dynamics of the membrane interaction and localisation of prodigiosin. *J Mol Graph Model*. 2020;98:107614.
72. Kimyon Ö, Das T, Ibugo AI, Kutty SK, Ho KK, Tebben J, Kumar N, Manefield M. Serratia Secondary Metabolite Prodigiosin Inhibits *Pseudomonas aeruginosa* Biofilm Development by Producing Reactive Oxygen Species that Damage Biological Molecules. *Front Microbiol*. 2016;7:972.
73. Melvin MS, Tomlinson JT, Saluta GR, Kucera GL, Lindquist N, Manderville RA. Double-Strand DNA Cleavage by Copper-Prodigiosin. *J Am Chem Soc*. 2000;122(26):6333–4.
74. Hazarika DJ, Gautom T, Parveen A, Goswami G, Barooah M, Modi MK, Boro RC. Mechanism of interaction of an endofungal bacterium *Serratia marcescens* D1 with its host and non-host fungi. *Plos One*. 2020;15(4):e0224051.
75. Clements T, Ndlovu T, Khan W. Broad-spectrum antimicrobial activity of secondary metabolites produced by *Serratia marcescens* strains. *Microbiol Res*. 2019;229:126329.
76. Dhar Purkayastha G, Mangar P, Saha A, Saha D. Evaluation of the biocontrol efficacy of a *Serratia marcescens* strain indigenous to tea rhizosphere for the management of root rot disease in tea. *Plos One*. 2018;13(2):e0191761.
77. Madison JD, Ouellette SP, Schmidt EL, Kerby JL. *Serratia marcescens* shapes cutaneous bacterial communities and influences survival of an amphibian host. *Proc Biol Sci*. 2019;286(1914):20191833.
78. Mamiya Y. Pathology of the Pine Wilt Disease Caused by *Bursaphelenchus xylophilus*. *Ann Rev Phytopathol*. 1983;21(1):201–20.
79. Yoon KH, Lee TY, Moon JH, Choi SY, Choi YJ, Mitchell RJ, Il Lee J. Consumption of Oleic Acid During Matrifagy in Free-Living Nematodes Alleviates the Toxic Effects of the Bacterial Metabolite Violacein. *Sci Rep*. 2020;10(1):8087.
80. Ballestrero F, Daim M, Penesyan A, Nappi J, Schleheck D, Bazzicalupo P, Di Schiavi E, Egan S. Correction: Antinematode Activity of Violacein and the Role of the Insulin/IGF-1 Pathway in Controlling Violacein Sensitivity in *Caenorhabditis elegans*. *PLoS One*. 2018;13(12):e0210026.
81. Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, Brauer M, Burnett R, Cercy K, Charlson FJ, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1659–724.
82. Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralte E, Gil J, Pérez-Tomás R. Prodigiosin from the supernatant of *Serratia marcescens* induces apoptosis in haematopoietic cancer cell lines. *Br J Pharmacol*. 2000;131(3):585–93.
83. Llagostera E, Soto-Cerrato V, Montaner B, Pérez-Tomás R. Prodigiosin Induces Apoptosis by Acting on Mitochondria in Human Lung Cancer Cells. *Ann New York Acad Sci* 2003, 1010(1):178–181.
84. Campàs C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, Pons G, Pérez-Tomás R, Gil J. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. *Leukemia*. 2003;17(4):746–50.
85. Diaz-Ruiz C, Montaner B, Perez-Tomas R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. *Histol Histopathol*. 2001;16(2):415–21.
86. Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. *Biochem Pharmacol*. 2004;68(7):1345–52.
87. Prabhu WV, Hong B, Allen JE, Zhang S, Lulla AR, Dicker DT, El-Deiry WS. Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated Δ Np73 Inhibition and p73 Activation. *Cancer Res*. 2016;76(7):1989–99.

88. Cheng S-Y, Chen N-F, Kuo H-M, Yang S-N, Sung C-S, Sung P-J, Wen Z-H, Chen W-F. Prodigiosin stimulates endoplasmic reticulum stress and induces autophagic cell death in glioblastoma cells. *Apoptosis*. 2018;23(5-6):314–28.
89. Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. *Biochem Pharmacol*. 2005;69(3):407–14.
90. Sessler JL, Eller LR, Cho W-S, Nicolaou S, Aguilar A, Lee JT, Lynch VM, Magda DJ. Synthesis, Anion-Binding Properties, and In Vitro Anticancer Activity of Prodigiosin Analogues. *Angewandte Chemie Int Edition*. 2005;44(37):5989–92.
91. Zhao C, Qiu SZ, He J, Peng Y, Xu HM, Feng ZQ, Huang HL, Du YL, Zhou YJ, Nie YQ. Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death. *Cancer Lett*. 2020;481:15–23.
92. Montaner B, Castillo-Ávila W, Martinell M, Öllinger R, Aymami J, Giralt E, Pérez-Tomás R. DNA Interaction and Dual Topoisomerase I and II Inhibition Properties of the Anti-Tumor Drug Prodigiosin. *Toxicol Sci*. 2005;85(2):870–9.
93. Anwar MM, Shalaby M, Embaby AM, Saeed H, Agwa MM, Hussein A. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights. *Sci Rep*. 2020;10(1):14706.
94. Ohkuma S, Sato T, Okamoto M, Matsuya H, Arai K, Kataoka T, Nagai K, Wasserman HH. Prodigiosins uncouple lysosomal vacuolar-type ATPase through promotion of H⁺/Cl⁻ symport. *Biochem J*. 1998;334(3):731–41.
95. Sato T, Konno H, Tanaka Y, Kataoka T, Nagai K, Wasserman HH, Ohkuma S. Prodigiosins as a New Group of H⁺/Cl⁻ Symporters That Uncouple Proton Translocators. *J Biol Chem*. 1998;273(34):21455–62.
96. Fürstner A, Reinecke K, Prinz H, Waldmann H. The Core Structures of Roseophilin and the Prodigiosin Alkaloids Define a New Class of Protein Tyrosine Phosphatase Inhibitors. *ChemBioChem*. 2004;5(11):1575–9.
97. Soliev AB, Hosokawa K, Enomoto K. Effects of prodigiosin family compounds from *Pseudoalteromonas* sp. 1020R on the activities of protein phosphatases and protein kinases. *J Enzyme Inhib Med Chem*. 2014;30(4):533–8.
98. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. *Nat Cell Biol*. 2007;9(10):1102–9.
99. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer*. 2017;17(9):528–42.
100. Razaghi A, Heimann K, Schaeffer PM, Gibson SB. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. *Apoptosis*. 2018;23(2):93–112.
101. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. *Oncotarget*. 2017;8(23):38022–43.
102. Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. *PLoS One*. 2014;9(10):e108694.
103. Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, Somfay A, Zatloukal P, Kazarnowicz A, Moezi MM, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. *Lung Cancer*. 2014;85(3):420–8.
104. Oki Y, Copeland A, Hagemeyer F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. *Blood*. 2012;119(9):2171–2.
105. Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. *Clin Lymphoma Myeloma Leukemia*. 2014;14(6):534–9.
106. Saraiva VS, Marshall JC, Cools-Lartigue J, Burnier MN. Cytotoxic effects of violacein in human uveal melanoma cell lines. *Melanoma Res*. 2004;14(5):421–4.
107. Mehta T, Vercruysee K, Johnson T, Ejirofor AO, Myles E, Quick QA. Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration. *Mol Med Rep*. 2015;12(1):1443–8.
108. de Carvalho DD, Costa FTM, Duran N, Haun M. Cytotoxic activity of violacein in human colon cancer cells. *Toxicol in Vitro*. 2006;20(8):1514–21.
109. Kodach LL, Bos CL, Duran N, Peppelenbosch MP, Ferreira CV, Hardwick JCH. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. *Carcinogenesis*. 2006;27(3):508–16.
110. Masuelli L, Pantanella F, La Regina G, Benvenuto M, Fantini M, Mattera R, Di Stefano E, Mattei M, Silvestri R, Schippa S, et al. Violacein, an indole-derived purple-colored natural pigment produced by *Janthinobacterium lividum*, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. *Tumor Biol*. 2016;37(3):3705–17.
111. Leal AM, de Queiroz JD, de Medeiros SR, Lima TK, Agnez-Lima LF. Violacein induces cell death by triggering mitochondrial membrane hyperpolarization in vitro. *BMC Microbiol*. 2015;15:115.
112. Bromberg N, Dreyfuss JL, Regatieri CV, Palladino MV, Duran N, Nader HB, Haun M, Justo GZ. Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. *Chem-Biol Interact*. 2010;186(1):43–52.
113. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Duran N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. *Blood*. 2004;104(5):1459–64.
114. Melo PD, Maria SS, Vidal BD, Haun M, Duran N. Violacein cytotoxicity and induction of apoptosis in V79 cells. *In Vitro Cell Dev-An*. 2000;36(8):539–43.
115. Goncalves PR, Rocha-Brito KJP, Fernandes MRN, Abrantes JL, Duran N, Ferreira-Halder CV. Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process. *Tumor Biol*. 2016;37(10):14049–58.
116. Queiroz KC, Milani R, Ruela-de-Sousa RR, Fuhler GM, Justo GZ, Zambuzzi WF, Duran N, Diks SH, Spek CA, Ferreira CV, Peppelenbosch MP. Violacein induces death of resistant leukaemia cells via kinome reprogramming, endoplasmic reticulum stress and Golgi apparatus collapse. *PLoS One*. 2012;7(10):e45362.
117. Balibar CJ, Walsh CT. In vitro biosynthesis of violacein from L-tryptophan by the enzymes VioA-E from *Chromobacterium violaceum*. *Biochemistry*. 2006;45(51):15444–57.
118. Platt D, Amara S, Mehta T, Vercruysee K, Myles EL, Johnson T, Tiriveedhi V. Violacein inhibits matrix metalloproteinase mediated CXCR4 expression: Potential anti-tumor effect in cancer invasion and metastasis. *Biochem Bioph Res Co*. 2014;455(1-2):107–12.
119. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. *Curr Pharm Design*. 2010;16(35):3903–20.
120. Antonisamy P, Kannan P, Aravinthan A, Duraipandiyar V, Arasu MV, Ignacimuthu S, Al-Dhabi NA, Kim JH. Gastroprotective activity of violacein isolated from *Chromobacterium violaceum* on indomethacin-induced gastric lesions in rats: investigation of potential mechanisms of action. *ScientificWorldJournal*. 2014;2014:616432.
121. Han SB, Kim HM, Kim YH, Lee CW, Jang E-S, Son KH, Kim SU, Kim YK. T-cell specific immunosuppression by prodigiosin isolated from *Serratia marcescens*. *Int J Immunopharmacol*. 1998;20(1-3):1–13.
122. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH. Prodigiosin blocks T cell activation by inhibiting interleukin-2/alpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. *J Pharmacol Exp Ther*. 2001;299(2):415–25.
123. Mortellaro A, Songia S, Gnocchi P, Ferrari M, Fornasiero C, D'Alessio R, Isetta A, Colotta F, Golay J. New immunosuppressive drug PNU156804 blocks IL-2 dependent proliferation and NF-kappa B and AP-1 activation. *J Immunol*. 1999;162(12):7102–9.
124. Han S-B, Lee CW, Yoon YD, Kang JS, Lee KH, Yoon WK, Kim YK, Lee K, Park S-K, Kim HM. Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. *Biochem Pharmacol*. 2005;70(10):1518–26.
125. Huh J-E, Koo H-J, Kim K-H, Yim J-H, Lee H-K, Sohn E-W, Pyo S-N. Immunosuppressive Effect of Prodigiosin on Murine Splenocyte and Macrophages. *Biomol Ther*. 2008;16(4):351–5.
126. Antonisamy P, Ignacimuthu S. Immunomodulatory, analgesic and antipyretic effects of violacein isolated from *Chromobacterium violaceum*. *Phytomed*. 2010;17(3-4):300–4.
127. Verinaud L, Lopes SC, Prado IC, Zanucoli F, Alves da Costa T, Di Gangi R, Issayama LK, Carvalho AC, Bonfanti AP, Niederauer GF, Duran N, Costa FT, Almeida AL, Höfling MA, Machado DR, Thomé R. Violacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T Cells. *PLoS One*. 2015;10(5):e0125409.
128. Alshatwi AA, Subash-Babu P, Antonisamy P. Violacein induces apoptosis in human breast cancer cells through up regulation of BAX, p53 and down regulation of MDM2. *Exp Toxicol Pathol*. 2016;68(1):89–97.
129. Venegas FA, Köllisch G, Mark K, Diederich WE, Kaufmann A, Bauer S, Chavarría M, Araya JJ, García-Piñeres AJ. The Bacterial Product Violacein Exerts an Immunostimulatory Effect Via TLR8. *Sci Rep*. 2019;9(1):13661.
130. Domröse A, Klein AS, Hage-Hülsmann J, Thies S, Svensson V, Classen T, Pietruszka J, Jaeger KE, Drepper T, Loeschcke A. Efficient recombinant

- production of prodigiosin in *Pseudomonas putida*. *Front Microbiol.* 2015;6:972.
131. Gallardo K, Candia JE, Remonsellez F, Escudero LV, Demergasso CS. The Ecological Coherence of Temperature and Salinity Tolerance Interaction and Pigmentation in a Non-marine *Vibrio* Isolated from Salar de Atacama. *Front Microbiol.* 2016;7:1943.
 132. Song MJ, Bae J, Lee DS, Kim CH, Kim JS, Kim SW, Hong SI. Purification and characterization of prodigiosin produced by integrated bioreactor from *Serratia* sp KH-95. *J Biosci Bioeng.* 2006;101(2):157–61.
 133. Williams RP, Gott CL, Green JA. Studies on Pigmentation of *Serratia Marcescens* V. *J Bacteriol.* 1961;81(3):376–9.
 134. Elahian F, Moghimi B, Dinmohammadi F, Ghamghami M, Hamidi M, Mirzaei SA. The Anticancer Agent Prodigiosin Is Not a Multidrug Resistance Protein Substrate. *DNA and Cell Biology.* 2013;32(3):90–7.
 135. Mendes AS, de Carvalho JE, Duarte MCT, Duran N, Bruns RE. Factorial design and response surface optimization of crude violacein for *Chromobacterium violaceum* production. *Biotechnol Lett.* 2001;23(23):1963–9.
 136. Pantanella F, Berlutti F, Passariello C, Sarli S, Morea C, Schippa S. Violacein and biofilm production in *Janthinobacterium lividum*. *J Appl Microbiol.* 2007;102(4):992–9.
 137. Rettori D, Duran N. Production, extraction and purification of violacein: an antibiotic pigment produced by *Chromobacterium violaceum*. *World J Microb Biot.* 1998;14(5):685–8.
 138. Wang HS, Jiang PX, Lu Y, Ruan ZY, Jiang RB, Xing XH, Lou K, Wei D. Optimization of culture conditions for violacein production by a new strain of *Duganella* sp B2. *Biochem Eng J.* 2009;44(2-3):119–24.
 139. DeMoss RD. Violacein. In: *Biosynthesis*; 1967. p. 77–81.
 140. Rodrigues AL, Trachtmann N, Becker J, Lohanatha AF, Blotenberg J, Bolten CJ, Korneli C, Lima AOD, Porto LM, Sprenger GA, et al. Systems metabolic engineering of *Escherichia coli* for production of the antitumor drugs violacein and deoxyviolacein. *Metab Eng.* 2013;20:29–41.
 141. Choi SY, Yoon KH, Lee JJ, Mitchell RJ. Violacein: Properties and Production of a Versatile Bacterial Pigment. *Biomol Res Int.* 2015;2015:465056.
 142. Duran N, Justo GZ, Duran M, Brocchi M, Cordi L, Tasic L, Castro GR, Nakazato G. Advances in *Chromobacterium violaceum* and properties of violacein-Its main secondary metabolite: A review. *Biotechnol Adv.* 2016;34(5):1030–45.
 143. Mun W, Kwon H, Im H, Choi SY, Monnappa AK, Mitchell RJ. Cyanide Production by *Chromobacterium piscinae* Shields It from *Bdellovibrio bacteriovorus* HD100 Predation. *mBio.* 2017;8(6):e01370-17.
 144. Cybulski O, Dygas M, Mikulak-Klucznik B, Siek M, Klucznik T, Choi SY, Mitchell RJ, Sobolev YI, Grzybowski BA. Concentric liquid reactors for chemical synthesis and separation. *Nature.* 2020;586(7827):57–63.
 145. Lin C, Jia X, Fang Y, Chen L, Zhang H, Lin R, Chen J. Enhanced production of prodigiosin by *Serratia marcescens* ZFSF02 in the form of pigment pellets. *Electron J Biotechn.* 2019;40:58–64.
 146. Kurbanoglu EB, Ozdal M, Ozdal OG, OF A. Enhanced production of prodigiosin by *Serratia marcescens* MO-1 using ram horn peptone. *Brazilian J Microbiol.* 2015;46(2):631–7.
 147. Casullo de Araújo HW, Fukushima K, GMC T. Prodigiosin Production by *Serratia marcescens* UCP 1549 Using Renewable-Resources as a Low Cost Substrate. *Molecules.* 2010;15(10):6931–40.
 148. Aruldass CA, Venil CK, Zakaria ZA, Ahmad WA. Brown sugar as a low-cost medium for the production of prodigiosin by locally isolated *Serratia marcescens* UTM1. *Int Biodeterioration Biodegradation.* 2014;95:19–24.
 149. Siva R, Subha K, Bhakta D, Ghosh AR, Babu S. Characterization and Enhanced Production of Prodigiosin from the Spoiled Coconut. *Appl Biochem Biotechnol.* 2011;166(1):187–96.
 150. Koo B-S, Hahn B-S, Sim J-S, Lee C-M, Kwon S-W, Baek H-J, Yoon S-H. Production of Violacein by a Novel Bacterium, *Massilia* sp. EP15224 Strain. *Korean J Microbiol Biotechnol.* 2014;42(4):317–23.
 151. Ahmad WA, Yusof NZ, Nordin N, Zakaria ZA, Rezali MF. Production and Characterization of Violacein by Locally Isolated *Chromobacterium violaceum* Grown in Agricultural Wastes. *Appl Biochem Biotechnol.* 2012;167(5):1220–34.
 152. Elkenawy NM, Yassin AS, Elhifnawy HN, Amin MA. Optimization of prodigiosin production by *Serratia marcescens* using crude glycerol and enhancing production using gamma radiation. *Biotechnol Rep.* 2017;14:47–53.
 153. Harris AKP, Williamson NR, Slater H, Cox A, Abbasi S, Foulds I, Simonsen HT, Leeper FJ, Salmond GPC. The *Serratia* gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species- and strain-dependent genome context variation. *Microbiology.* 2004;150(11):3547–60.
 154. Williamson NR, Simonsen HT, Ahmed RAA, Goldet G, Slater H, Woodley L, Leeper FJ, Salmond GPC. Biosynthesis of the red antibiotic, prodigiosin, in *Serratia*: identification of a novel 2-methyl-3-n-amylyl-pyrrole (MAP) assembly pathway, definition of the terminal condensing enzyme, and implications for undecylprodigiosin biosynthesis in *Streptomyces*. *Mol Microbiol.* 2005;56(4):971–89.
 155. Williams RP, Goldschmidt ME, Gott CL. Inhibition by temperature of the terminal step in biosynthesis of prodigiosin. *Biochem Biophys Res Commun.* 1965;19(2):177–81.
 156. Morrison DA. Prodigiosin synthesis in mutants of *Serratia marcescens*. *J Bacteriol.* 1966;91(4):1599–604.
 157. Qadri SMH, Williams RP. Role of Methionine in Biosynthesis of Prodigiosin by *Serratia marcescens*. *J Bacteriol.* 1973;116(3):1191–8.
 158. Fineran PC, Slater H, Everson L, Hughes K, Salmond GPC. Biosynthesis of tripyrrole and β -lactam secondary metabolites in *Serratia*: integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carbapenem antibiotic production. *Mol Microbiol.* 2005;56(6):1495–517.
 159. Slater H, Crow M, Everson L, Salmond GPC. Phosphate availability regulates biosynthesis of two antibiotics, prodigiosin and carbapenem, in *Serratia* via both quorum-sensing-dependent and -independent pathways. *Mol Microbiol.* 2008;47(2):303–20.
 160. Thomson NR, Crow MA, McGowan SJ, Cox A, Salmond GPC. Biosynthesis of carbapenem antibiotic and prodigiosin pigment in *Serratia* is under quorum sensing control. *Mol Microbiol.* 2002;36(3):539–56.
 161. Coulthurst SJ, Kurz CL, GPC S. *luxS* mutants of *Serratia* defective in autoinducer-2-dependent 'quorum sensing' show strain-dependent impacts on virulence and production of carbapenem and prodigiosin. *Microbiology.* 2004;150(6):1901–10.
 162. Pemberton JM, Vincent KM, Penfold RJ. Cloning and Heterologous Expression of the Violacein Biosynthesis Gene-Cluster from *Chromobacterium-Violaceum*. *Curr Microbiol.* 1991;22(6):355–8.
 163. Sanchez C, Brana AF, Mendez C, Salas JA. Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis. *ChemBiochem.* 2006;7(8):1231–40.
 164. Balibar CJ, Walsh CT. In vitro biosynthesis of violacein from L-tryptophan by the enzymes *VioA-E* from *Chromobacterium violaceum*. *Biochemistry-US.* 2006;45(51):15444–57.
 165. August PR, Grossman TH, Minor C, Draper MP, MacNeil IA, Pemberton JM, Call KM, Holt D, Osburne MS. Sequence analysis and functional characterization of the violacein biosynthetic pathway from *Chromobacterium violaceum*. *J Mol Microbiol Biotechnol.* 2000;2(4):513–9.
 166. McClean KH, Winson MK, Fish L, Taylor A, Chhabra SR, Camara M, Daykin M, Lamb JH, Swift S, Bycroft BW, et al. Quorum sensing and *Chromobacterium violaceum*: exploitation of violacein production and inhibition for the detection of N-acylhomoserine lactones. *Microbiology.* 1997;143(12):3703–11.
 167. Wang Y, Ikawa A, Okaue S, Taniguchi S, Osaka I, Yoshimoto A, Kishida Y, Arakawa R, Enomoto K. Quorum sensing signaling molecules involved in the production of violacein by *Pseudoalteromonas*. *Biosci Biotechnol Biochem.* 2008;72(7):1958–61.
 168. Fukumoto A, Murakami C, Anzai Y, Kato F. Maniwamycins: new quorum-sensing inhibitors against *Chromobacterium violaceum* CV026 were isolated from *Streptomyces* sp. TOHO-M025. *J Antibiot (Tokyo).* 2016;69(5):395–9.
 169. Ohta T, Fukumoto A, Iizaka Y, Kato F, Koyama Y, Anzai Y. Quorum Sensing Inhibitors against *Chromobacterium violaceum* CV026 Derived from an Actinomycete Metabolite Library. *Biol Pharm Bull.* 2020;43(1):179–83.
 170. Harrison AM, Soby SD. Reclassification of *Chromobacterium violaceum* ATCC 31532 and its quorum biosensor mutant CV026 to *Chromobacterium subtsugae*. *AMB Express.* 2020;10(1):202.
 171. Su C, Xiang Z, Liu Y, Zhao X, Sun Y, Li Z, Li L, Chang F, Chen T, Wen X, Zhou Y, Zhao F. Analysis of the genomic sequences and metabolites of *Serratia surfactantifaciens* sp. nov. YD25T that simultaneously produces prodigiosin and serrawettin W2. *BMC Genomics.* 2016;17(1):865.
 172. Li P, Kwok AH, Jiang J, Ran T, Xu D, Wang W, Leung FC. Comparative genome analyses of *Serratia marcescens* FS14 reveals its high antagonistic potential. *PLoS One.* 2015;10(4):e0123061.
 173. Smith HJ, Foreman CM, Akiyama T, Franklin MJ, Devitt NP, Ramaraj T. Genome Sequence of *Janthinobacterium* sp. CG23_2, a Violacein-Producing

- Isolate from an Antarctic Supraglacial Stream. *Genome Announc.* 2016;4(1):e01468-15.
174. Valdes N, Soto P, Cottet L, Alarcon P, Gonzalez A, Castillo A, Corsini G, Tello M. Draft genome sequence of *Janthinobacterium lividum* strain MTR reveals its mechanism of capnophilic behavior. *Stand Genomic Sci.* 2015;10:110.
 175. Wu X, Deuschbauer AM, Kazakov AE, Wetmore KM, Cwick BA, Walker RM, Novichkov PS, Arkin AP, Chakraborty R. Draft Genome Sequences of Two *Janthinobacterium lividum* Strains, Isolated from Pristine Groundwater Collected from the Oak Ridge Field Research Center. *Genome Announc.* 2017;5(26):e00582-17.
 176. Doing G, Perron GG, Jude BA. Draft Genome Sequence of a Violacein-Producing *Iodobacter* sp. from the Hudson Valley Watershed. *Genome Announc.* 2018;6(1):e01428-17.
 177. Jude BA. Draft Genome Sequence of a *Chitinimonas* Species from Hudson Valley Waterways That Expresses Violacein Pigment. *Microbiol Resour Announc.* 2019;8(35):e00683-19.
 178. Lamendella R, Jude BA. Draft Genome Sequences of Violacein-Producing *Duganella* sp. Isolates from a Waterway in Eastern Pennsylvania. *Microbiol Resour Announc.* 2018;7(12):e01196-18.
 179. Bettina AM, Doing G, O'Brien K, Perron GG, Jude BA. Draft Genome Sequences of Phenotypically Distinct *Janthinobacterium* sp. Isolates Cultured from the Hudson Valley Watershed. *Genome Announc.* 2018;6(3):e01426-17.
 180. O'Brien K, Perron GG, Jude BA. Draft Genome Sequence of a Red-Pigmented *Janthinobacterium* sp. Native to the Hudson Valley Watershed. *Genome Announc.* 2018;6(1):e01429-17.
 181. Kwon SK, Park YK, Kim JF. Genome-wide screening and identification of factors affecting the biosynthesis of prodigiosin by *Hahella chejuensis*, using *Escherichia coli* as a surrogate host. *Appl Environ Microbiol.* 2010;76(5):1661–8.
 182. Dauenhauer SA, Hull RA, Williams RP. Cloning and expression in *Escherichia coli* of *Serratia marcescens* genes encoding prodigiosin biosynthesis. *J Bacteriol.* 1984;158(3):1128–32.
 183. Fang MY, Zhang C, Yang S, Cui JY, Jiang PX, Lou K, Wachi M, Xing XH. High crude violacein production from glucose by *Escherichia coli* engineered with interactive control of tryptophan pathway and violacein biosynthetic pathway. *Microb Cell Fact.* 2015;14(1):8.
 184. Immanuel SRC, Banerjee D, Rajankar MP, Raghunathan A. Integrated constraints based analysis of an engineered violacein pathway in *Escherichia coli*. *Biosystems.* 2018;171:10–9.
 185. Rodrigues AL, Göcke Y, Bolten C, Brock NL, Dickschat JS, Wittmann C. Microbial production of the drugs violacein and deoxyviolacein: analytical development and strain comparison. *Biotechnol Lett.* 2011;34(4):717–20.
 186. Wilkinson MD, Lai HE, Freemont PS, Baum J. A Biosynthetic Platform for Antimalarial Drug Discovery. *Antimicrob Agents Chemother.* 2020;64(5):e02129-19.
 187. C-Y H, Guo Y, Liu L, Zhang N-X, Gao C-X, Yang X-Q, Yi J. Genetic control of violacein biosynthesis to enable a pigment-based whole-cell lead biosensor. *Rsc Adv.* 2020;10(47):28106–13.
 188. Jiang Y, Sigmund F, Reber J, Deán-Ben XL, Glasl S, Kneipp M, Estrada H, Razansky D, Ntziachristos V, Westmeyer GG. Violacein as a genetically controlled, enzymatically amplified and photobleaching-resistant chromophore for optoacoustic bacterial imaging. *Sci Rep.* 2015;5:11048.
 189. Jeschek M, Gerngross D, Panke S. Rationally reduced libraries for combinatorial pathway optimization minimizing experimental effort. *Nat Commun.* 2016;7:11163.
 190. Chuang J, Boeke JD, Mitchell LA. Coupling Yeast Golden Gate and VEGAS for Efficient Assembly of the Violacein Pathway in *Saccharomyces cerevisiae*. In: *Synthetic Metabolic Pathways*; 2018. p. 211–25.
 191. Tong Y, Zhou J, Zhang L, Xu P. A Golden-Gate Based Cloning Toolkit to Build Violacein Pathway Libraries in *Yarrowia lipolytica*. *ACS Synthetic Biol.* 2021;10(1):115–24.
 192. NCBI PubMed <https://pubmed.ncbi.nlm.nih.gov/>. Accessed 20 Jan 2021.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

